一个随机试验比较同时与顺序辐射和内分泌疗法在早期阶段,激素敏感乳腺癌
Sharon F McGee1,2, Mark Clemons1,2, Gregory Pond3
1Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Current oncology (Toronto, Ont.)
|August 28, 2024
概括
在早期乳腺癌中,同步与顺序内分泌和放射治疗对内分泌治疗毒性没有显著差异. 这一发现支持早期乳腺癌患者的辐射和内分泌治疗的个性化治疗时间.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 内分泌治疗疗法 内分泌治疗疗法
背景情况:
- 在早期乳腺癌 (EBC) 中,人们对与内分泌疗法和放射治疗同时进行的毒性存在担忧.
- 优化治疗顺序对于管理EBC患者的副作用至关重要.
研究的目的:
- 为了比较内分泌疗法毒性,同时和顺序给予内分泌疗法和放射治疗在荷尔蒙反应的EBC.
- 根据个体患者的需要,提供证据来定制辐射和内分泌疗法的时间.
主要方法:
- 一个务实的,多中心随机试验,比较并发与顺序辅助内分泌疗法和放射治疗.
- 主要结局:从基线到放射治疗后3个月内,内分泌治疗毒性 (FACT-ES得分) 的变化.
- 133名患者随机分为并发治疗,127人分为顺序治疗;数据收集于2019年9月至2021年1月.
主要成果:
- 同时和顺序组之间没有观察到内分泌治疗毒性变化的显著差异 (p = 0.87).
- 同时治疗的中位数毒性变化得分为-4.9,顺序治疗的中位数是-5.1.
- 这项研究包括大多数绝经后患者 (72.7%) 的第一阶段疾病 (65.8%).
结论:
- 同时和顺序的内分泌疗法与放射治疗导致类似的内分泌疗法相关的毒性在EBC.
- 对于荷尔蒙反应良好的EBC患者,治疗时间可以个性化,平衡疗效和毒性.
- 这项研究是第一个直接比较这些测序策略关于毒性结果的研究.
相关概念视频
01:12Hazard Ratio
99
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
99
01:20Comparing the Survival Analysis of Two or More Groups
162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162